SCHEMBL24257961

SCHEMBL24257961

O=C(O)CCCCCCCc1ccc(CCOc2ccc(S(=O)(=O)Nc3ncc(C(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)cn3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
PKM P14618 1/20 0.39
S1PR1 P21453 3/20 0.37
CA2 P00918 1/20 0.37
S1PR3 Q99500 1/20 0.37
S1PR5 Q9H228 1/20 0.37
TDP1 Q9NUW8 3/20 0.37
POLB P06746 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
SGMS1 Q86VZ5 3/20 0.36
TBXA2R P21731 1/20 0.36
TBXAS1 P24557 1/20 0.36
FABP1 P07148 1/20 0.36
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22080442 1.00 SMN1; SMN2 (0.39) SMN1; SMN2PKMS1PR1CA2S1PR3
SCHEMBL24257953 0.95 SMN1; SMN2 (0.40) SMN1; SMN2PKMS1PR1CA2S1PR3
SCHEMBL31682070 0.95 NPC1 (0.40) SMN1; SMN2PKMCA2TDP1NPC1
SCHEMBL22029401 0.95 NPC1 (0.40) SMN1; SMN2PKMCA2TDP1NPC1
SCHEMBL24257988 0.95 NPC1 (0.40) SMN1; SMN2PKMCA2TDP1NPC1
SCHEMBL22080333 0.95 NPC1 (0.40) SMN1; SMN2PKMCA2TDP1NPC1
SCHEMBL22079946 0.95 NPC1 (0.40) SMN1; SMN2PKMCA2TDP1NPC1
SCHEMBL24257857 0.95 TDP1 (0.44) SMN1; SMN2PKMCA2TDP1POLB
SCHEMBL22079977 0.95 TDP1 (0.44) SMN1; SMN2PKMCA2TDP1POLB
SCHEMBL31682051 0.95 TDP1 (0.44) SMN1; SMN2PKMCA2TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3893934-B1 INSULIN CONJUGATES SANOFI SA (FR) 2025-09-10 EP disclosed
US-20220048968-A1 INSULIN CONJUGATES SANOFI (FR) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048968-A1 INSULIN CONJUGATES IAPP, INSR, IGF1R SMN1; SMN2 1332/4885PKM 1743/4885S1PR1 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.